Lund, Sweden, 21 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX) , a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, presents the company at Redeye Life Science Seminar on Friday 24 November (10:15 am CET) at Haymarket in Stockholm, Sweden. The presentation can be followed in real-time at www.redeye.se .
The presentation will also be accessible after the event at www.redeye.se and on the company page at Redeye Univers e ( www.redeye.se/company/alligator-bioscience ).
For further information:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 286 44 95
E-m ail: [email protected] .
The information was submitted for publication, through the agency of the contact person set out above, at 1:30 p.m. CET on 21 November 2017.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527) and novel research candidates. ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 45 employees. For more information, please visit www.alligatorbioscience.com .
Powered by WPeMatico
